All In Biotech

NDA 203993 · Lundbeck Pharms LLC

Onfi

Clobazam · Oral · Benzodiazepine

Orphan

Last checked: Nov 19, 2026Latest source record: Mar 12, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2012

Dec 14, 2012

Approved uses

1

Original approval plus efficacy supplements

Registered trials

23

10 Phase 3, 2 recruiting

FAERS reports

24,918

19,680 serious, 1,592 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation [see Warnings and Precautions ( 5.1 ), Drug Interactions ( 7.1 )] . The use of benzodiazepines, including ONFI, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes....

What it is approved for

From the label in effect Oct 16, 2026.

ONFI ® (clobazam) is indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older. ONFI is a benzodiazepine indicated for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older ( 1 )

Mechanism: The exact mechanism of action for clobazam, a 1,5-benzodiazepine, is not fully understood but is thought to involve potentiation of GABAergic neurotransmission resulting from binding at the benzodiazepine site of the GABA A receptor.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ONFI · CLOBAZAM 2.5MG/ML · SUSPENSION, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Clobazam" as an intervention, any sponsor and status, largest first.

All 23 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • seizure5,137
  • drug ineffective3,354
  • off label use2,341
  • somnolence1,987
  • drug interaction1,200
  • fatigue1,179
  • epilepsy870
  • condition aggravated859
  • generalised tonic-clonic seizure774
  • status epilepticus738
  • pneumonia719
  • aggression715

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200446
200573
200669
200784
2008111
2009127
2010168
2011140
2012656
2013723
2014787
2015997
20161,142
20171,303
20181,257
20192,057
20201,917
20212,650
20222,014
20232,184
20242,401
20252,226
20261,785

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Onfi (Clobazam)

2024 spending

$31.4M

Beneficiaries

1,143

9,712 claims

Per beneficiary

$27,500

$37.61 per unit

View as table
YearSpending
2020$32,346,833
2021$30,009,530
2022$29,811,572
2023$31,539,755
2024$31,432,691

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 203 on PubMed

Sponsor: Lundbeck Pharms LLC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.